Pulished Date October, 2018
ID: 765
Share on
Share on

North America Leukemia Therapeutics Market By Disease Condition (chronic Lymphatic Leukemia, Acute Lymphatic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia), By Diagnosis (CT Scan, Biopsy, MRI), By Treatments (chemotherapy, Radiation Therapy, Immunotherapy, Surgery, Targeted Therapy, Bone Marrow Transplant, Stem Cell Therapy), By Drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 765
Pages: 145

North America Leukemia Therapeutics market has been estimated at USD 2.22 Billion in 2018 and is projected to reach USD 3.4 Billion by 2023, at a CAGR of 8.9% during the forecast period from 2018 to 2023.  Leukemia is the cancer of the WBC or the bone marrow, which occurs due to abnormal increase in the count of white blood cells. It is identified by the type of the blood cell that is affected (lymphocytic or myelocytic) and by the spread of the diseases (either acute or chronic). It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide.

The North American market for Leukemia Therapeutics is mainly increasing due to increasing occurrence of leukemia. Also, there is raise in awareness regarding the disease, drugs and treatments due to increasing involvement of R&D in coming up with new ways of treatments and drugs. Due to this, the market is highly driven. But due to high cost of treatment and drugs, there is a chance of drop in the market growth.

North America market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.

Geographically, North America market for Leukemia Therapeutics is segmented into U.S.A and Canada. North America holds the largest share in global market, followed by Europe. A number of factors such as rising prevalence of leukemia, and increasing penetration of companies into the market with increasing R&D involvement are creating opportunities for market growth in Leukemia Therapeutics market in the North American region.

Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of North America Leukemia Therapeutics market.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Disease Condition                              

                                5.1.1 Chronic Lymphatic Leukemia           

                                5.1.2 Acute Lymphatic Leukemia              

                                5.1.3 Chronic Myeloid Leukemia               

                                5.1.4 Acute Myeloid Leukemia  

                5.2 By Diagnosis                               

                                5.2.1 CT scan     

                                5.2.2 Biopsy       

                                5.2.3 MRI            

                5.3 By Treatments                          

                                5.3.1 Chemotherapy      

                                5.3.2 Radiation therapy

                                5.3.3 Immunotherapy   

                                5.3.4 Surgery     

                                5.3.5 Targeted Therapy

                                5.3.6 Bone marrow transplant   

                                5.3.7 Stem Cell Therapy

                5.4 By Drugs                      

                                5.4.1 Gleevec    

                                5.4.2 Sapacitabine           

                                5.4.3 GA101       

                                5.4.4 Vasaroxine              

                                5.4.5 Tosedosat               

6. Geographical Analysis                                              

                                6.1 Introduction               

                                6.2 United States            

                                6.3 Canada         

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials                               

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target     

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target   

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.            

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 F. Hoffmann-La Roche Ltd                    

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 GlaxoSmithKline Pharmaceuticals Limited                     

                9.3 Novartis International AG                    

                9.4 Bristol-Myers Squibb                              

                9.5 Eisai Co. Ltd                

                9.6 Biogen Idec                                

                9.7 ERYtech Pharma                       

                9.8 Celgene Corporation                              

                9.9 Genmab A/S                              

                9.10 Cephalon Inc.                          

                9.11 Clavis Pharma                          

                9.12 Pfizer Inc.                  

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

 

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Leukemia Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. North America Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  3. North America Cchronic Lymphatic Leukemia Market By Region, From 2018-2023 (USD Billion)
  4. North America Acute Lymphatic Leukemia Market By Region, From 2018-2023 (USD Billion)
  5. North America Chronic Myeloid Leukemia Market By Region, From 2018-2023 (USD Billion)
  6. North America Acute Myeloid Leukemia Market By Region, From 2018-2023 (USD Billion)
  7. North America Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  8. North America Leukemia CT scan Market By Region, From 2018-2023 (USD Billion)
  9. North America Leukemia Biopsy Market By Region, From 2018-2023 (USD Billion)
  10. North America Leukemia MRI Market By Region, From 2018-2023 (USD Billion)
  11. North America Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  12. North America Leukemia Chemotherapy Market By Region, From 2018-2023 (USD Billion)
  13. North America Leukemia Radiation Therapy Market By Region, From 2018-2023 (USD Billion)
  14. North America Leukemia Immunotherapy Market By Region, From 2018-2023 (USD Billion)
  15. North America Leukemia Surgery Market By Region, From 2018-2023 (USD Billion)
  16. North America Leukemia Targeted Therapy Market By Region, From 2018-2023 (USD Billion)
  17. North America Leukemia Bone marrow transplant Market By Region, From 2018-2023 (USD Billion)
  18. North America Leukemia Stem Cell Therapy Market By Region, From 2018-2023 (USD Billion)
  19. North America Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
  20. North America Leukemia Gleevec Market By Region, From 2018-2023 (USD Billion)
  21. North America Leukemia Sepecitabine Market By Region, From 2018-2023 (USD Billion)
  22. North America Leukemia GA101 Market By Region, From 2018-2023 (USD Billion)
  23. North America Leukemia Vasaroxine Market By Region, From 2018-2023 (USD Billion)
  24. North America Leukemia Tosedosat Market By Region, From 2018-2023 (USD Billion)
  25. United States Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  26. United States Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  27. United States Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  28. United States Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)
  29. Canada Leukemia Therapeutics Market By Disease condition, From 2018-2023 (USD Billion)
  30. Canada Leukemia Therapeutics Market By Diagnosis, From 2018-2023 (USD Billion)
  31. Canada Leukemia Therapeutics Market By Treatments, From 2018-2023 (USD Billion)
  32. Canada Leukemia Therapeutics Market By Drugs, From 2018-2023 (USD Billion)

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients